Update on National HPV Vaccination Programme

1. At a Glance

• National HPV Vaccination Programme is India's first government-funded, population-scale rollout of the Human Papillomavirus (HPV) vaccine to prevent cervical cancer, using single-dose Gardasil-4 at government facilities free of cost [S1][S2].
• Targets ~1.2 crore girls aged 14 years across all 36 States/UTs under a 90-day intensive drive launched 28 February 2026 from Ajmer, Rajasthan by the PM [S1][S2].
• UPSC relevance: GS-II (health, vulnerable groups, welfare schemes) and GS-III (S&T — indigenous biotech, public-health economics).

2. Why in the News

• 17 March 2026: Ministry of Health & Family Welfare (MoHFW) issued an "Update on National HPV Vaccination Programme" reporting rollout status three weeks after launch [S1].
• 28 February 2026: PM Modi flagged off the nationwide HPV vaccination campaign from Ajmer, Rajasthan [S2].
• The drive operationalises the Interim Budget 2024-25 announcement (FM Sitharaman) to encourage HPV vaccination for girls in the 9–14 age band [S5].

3. Background & Evolution

• 2008: HPV vaccines (Gardasil, Cervarix) first licensed in India; demonstration projects in Andhra Pradesh & Gujarat suspended in 2010 after adverse-event controversies.
• 2017–18: Sikkim, Punjab, Delhi pilot state-level HPV programmes for adolescent girls.
• September 2022: DBT–BIRAC + Serum Institute of India + Gates Foundation launch CERVAVAC — India's first indigenously developed quadrivalent HPV vaccine under 'Grand Challenges India' [S2].
• 2022–23: NTAGI (National Technical Advisory Group on Immunisation) recommended HPV inclusion in UIP [S3].
• 1 Feb 2024: Interim Budget announced HPV vaccination for 9–14-year-old girls [S5].
• 28 Feb 2026: Nationwide free campaign launched [S2].

4. Core Static Facts

• Nodal Ministry: Ministry of Health & Family Welfare (MoHFW) [S1].
• Vaccine used: Gardasil-4 — quadrivalent, covers HPV types 6, 11, 16, 18 [S2].
• Schedule: Single dose (aligned with WHO SAGE 2022 recommendation) [S2].
• Target cohort: Girls aged 14 years; those turning 15 within 90 days of launch also eligible [S2].
• Beneficiaries: ~1.2 crore girls across 36 States/UTs [S1].
• Delivery sites: Ayushman Arogya Mandirs–PHCs, CHCs, Sub-District/District Hospitals, Government Medical Colleges [S1].
• Indigenous vaccine: CERVAVAC by Serum Institute of India (DBT–BIRAC + Gates Foundation partnership) [S2].
• WHO Global Strategy target (Nov 2020): 90-70-90 by 2030 — 90% HPV vaccination of girls by age 15, 70% screening, 90% treatment of pre-cancer/cancer [S3].
• Disease burden: India contributes ~1/6th of global future cervical cancer cases; 2nd leading cancer in Indian women [S3].

5. Multi-Dimensional Analysis

Social / Gender - Cervical cancer is a major killer of Indian women; programme advances women-centric preventive healthcare in line with "Nari Shakti" framing of Budget 2024 [S5]. - Free delivery in rural and underserved areas tackles the inverse-care equity gap [S1].

Scientific / Technological - Adoption of single-dose schedule reflects WHO SAGE 2022 evidence on equivalent efficacy, cutting cost & cold-chain load [S2][S3]. - CERVAVAC marks Atmanirbhar Bharat in biologics, reducing import dependence on Merck/GSK vaccines [S2].

Economic / Fiscal - Free-of-cost universal rollout converts a previously high-cost (₹2,000–4,000/dose) private vaccine into a public good, expanding fiscal commitment under National Health Mission.

Administrative / Federal - Implemented via existing Universal Immunisation Programme (UIP) logistics; relies on state health departments and co-WIN-style digital tracking; Education Department coordination for school-based outreach [S2].

Public-Health / Strategic - Aligns India to WHO 2030 90-70-90 elimination strategy; modelling shows elimination feasible by 2062 with 10.6 mn lives saved by 2120 [S3].

6. Recent Developments (last 12-18 months)

• 1 Feb 2024: FM announced HPV vaccination push for 9–14 girls in Interim Budget [S5].
• 2024: Union Minister Dr Jitendra Singh hosted "Together Against HPV" Conclave [S4].
• 28 Feb 2026: PM launches nationwide drive from Ajmer [S2].
• 17 Mar 2026: MoHFW status update — multi-faceted approach (screening + early diagnosis + treatment) being scaled [S1].

7. Prelims Hooks

• Vaccine deployed: Gardasil-4 (quadrivalent: HPV 6/11/16/18) [S2].
• Dose schedule: single dose (not 2 or 3) [S2].
• Indigenous Indian HPV vaccine: CERVAVAC by Serum Institute of India [S2].
• CERVAVAC developed under DBT-BIRAC programme: Grand Challenges India with Gates Foundation [S2].
• Launch date of national drive: 28 February 2026; launched from Ajmer, Rajasthan by PM [S2].
• Target age: 14 years (with 15-yr extension in 90-day window) [S2].
• Target beneficiaries: ~1.2 crore girls, all 36 States/UTs [S1].
• Implementing ministry: MoHFW (not Ministry of Women & Child Development) [S1].
• Delivery sites include Ayushman Arogya Mandirs, PHCs, CHCs, DHs, Govt. Medical Colleges [S1].
• WHO Global Strategy to eliminate cervical cancer launched: November 2020 [S3].
• WHO elimination targets: 90-70-90 by 2030 [S3].
• Cervical cancer rank among Indian women's cancers: 2nd (after breast); India ≈ 1/6 of global burden [S3].
• Advisory body recommending UIP inclusion: NTAGI [S3].

8. Mains Relevance

• GS-II — Issues relating to health; Government policies for vulnerable sections.
• GS-III — Science & Technology: indigenisation, biotechnology.
• Possible question stems: 1. "Examine the public-health and equity rationale behind India's switch to a single-dose, government-funded HPV vaccination programme. What implementation bottlenecks remain?" 2. "Discuss how the rollout of CERVAVAC exemplifies the Atmanirbhar Bharat vision in the biopharmaceutical sector." 3. "India's progress towards the WHO's 90-70-90 cervical cancer elimination target depends on more than vaccination. Critically analyse."

9. Related Topics to Study Next

• Universal Immunisation Programme (UIP) & Mission Indradhanush — vehicle for HPV scale-up.
• Ayushman Arogya Mandirs (erstwhile HWCs) — delivery platform [S1].
• National Programme for Prevention & Control of NCDs (NP-NCD) — houses cancer screening.
• WHO Global Strategy on Cervical Cancer Elimination (2020) [S3].
• CERVAVAC & DBT-BIRAC ecosystem — biotech indigenisation.
• NTAGI — vaccine policy advisory architecture.
• U-WIN platform — digital immunisation tracking.
• Interim Budget 2024-25 health announcements [S5].

10. Common Errors / Trap Areas

• Vaccine confusion: Programme uses Gardasil-4 (quadrivalent), NOT Gardasil-9 (nonavalent) or Cervarix (bivalent) [S2].
• Dose schedule: It is single-dose, not the older 2- or 3-dose regimen.
• Ministry: MoHFW (not WCD, not AYUSH) [S1].
• CERVAVAC vs Gardasil: CERVAVAC is the indigenous SII product; the national campaign at launch primarily uses Gardasil-4 — don't equate them [S2].
• WHO targets: 90-70-90 (vaccinate-screen-treat) by 2030, elimination defined as <4 cases per 1 lakh women [S3].
• Age: Primary cohort is 14 years under this national launch, even though global WHO band is 9–14.

11. Sources

• [S1] Update on National HPV Vaccination Programme — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2241079 — (tier 1)
• [S2] PM Launches Nationwide HPV Vaccination Drive for 14-Year-Old Girls from Ajmer — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2233906 — (tier 1)
• [S3] Current status of HPV vaccination in India's cervical cancer prevention efforts — https://www.iarc.who.int/news-events/current-status-of-human-papillomavirus-vaccination-in-indias-cervical-cancer-prevention-efforts/ — (tier 2)
• [S4] "Together Against HPV" Conclave — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2085299 — (tier 1)
• [S5] Nari Shakti — FM Announces Vaccination to Prevent Cervical Cancer (Interim Budget 2024-25) — https://www.pib.gov.in/PressReleaseIframePage.aspx?PRID=2001172 — (tier 1)